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We recently encountered a unique case of breast
silicone implant-associated ALK-1 negative anaplas-
tic large cell lymphoma (ALCL) in a female with a
remote history of breast carcinoma, which presented
as a sinusoidal infiltrate in an axillary lymph node
(LN) and had a highly complex karyotype.
A 68-year-old female had undergone right breast
lumpectomy followed by right modified radical
mastectomy with axillary LN dissection in 1991 for
infiltrating moderately differentiated ductal carcino-
ma. No lymphovascular invasion or LN involvement
was identified. She received six cycles of chemother-
apy and 5 years of tamoxifen. In January of 1992, the
patient underwent right breast reconstruction with a
silicone implant. Sixteen years later the patient
developed right axillary lymphadenopathy. Her past
medical history was significant only for the prior
breast carcinoma and biliary cirrhosis. She had no
history of non-Hodgkin or Hodgkin lymphoma. Right
axillary LN biopsy showed a large cell neoplasm
infiltrating and expanding the sinuses (Figure1A). An
exhaustive staining panel led to the diagnosis of an
ALK-1 negative ALCL (Figure1B). A staging bone
marrow biopsy showed no evidence of lymphoma.
A subsequent FDG-PET/CT scan showed a hyper-
metabolic focus (maximum SUV 7.4) posterior to the
breast implant. The grossly intact implant
was removed with capsulectomy. Histologic review
of the fibrotic capsular tissue showed an infiltrate of
large neoplastic cells as seen previously (Figure 2A),
which had the following phenotype (Figure 2B):
CD457/þ, CD30þ, CD15þ, EMAþ, MUM1þ,
CD2þ and CD4þ. These cells did not express CD3,
CD5, CD7, CD8, ALK-1, CD56, CD20, PAX5,
CD79a, OCT2, CD138, p53, or cytotoxic T-cell
granule constituents (TIA-1, granzyme-B and perfor-
in). In situ hybridisation for EBV mRNA was negative.
The proliferation rate, as assessed with a stain
for Ki-67, was 490%. Cytogenetic analysis revealed
highly complex clonal chromosome abnormalities,
penta-ploidy range metaphases and homogenously





(p15.1q22.1)[7]. FISH analysis using T-cell
receptor alpha/delta break-apart, ALK break-apart
and D7S486/CEP7 probes showed no evidence
of rearrangement or deletion. PCR analysis
showed clonal T-cell receptor beta gene rearrange-
ment.
Four months after initial diagnosis, the patient
developed left-sided (contralateral) axillary lympha-
denopathy, and a LN biopsy again disclosed sinu-
soidal infiltrates of ALCL. After completion of six
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cycles of CHOP (cyclophosphamide, vincristine,
doxorubicin, and prednisone) therapy, a repeat
PET/CT scan showed a mildly hypermetabolic focus
in the dome of the liver (SUV 2.8) and 2 minimally
hypermetabolic foci in the left breast (SUV 0.7),
suspicious for residual disease. Of note, she had also
been under treatment for primary biliary cirrhosis
and these lesions were not biopsied, therefore, it
is unclear if the imaging findings represented
lymphoma or a reactive condition.
Our case represents an ALK-1 negative ALCL
arising in a breast capsule, in association with a
silicone implant and bilateral axillary LN involve-
ment. This case thus adds to the growing literature of
breast prosthesis-associated lymphomas, with 17
cases published thus far [1–3], as well as a series of
six unpublished cases [4].
A recent case report by Wong et al. and the
seven other ALK-1 negative ALCL cases reviewed
in their article presented in the breast without
nodal involvement [2]. Only one patient had a
relapse, while all others were living free of disease.
The four cases reported by Roden et al. were also
ALK-1 negative ALCL, which were described as
‘therapy-resistant seroma’ adjacent to saline or
silicone implants; neoplastic cells being identified
only in the serous fluid without tissue invasion [1].
Three of their patients were staged and showed no
evidence of systemic disease. Three of the patients
were alive without evidence of disease after a mean
follow-up of 13 months (range of 9–20 months),
suggesting that these lymphomas represent indolent
T-cell lymphoproliferative disorders. Popplewell
et al. described six cases of primary ALCL,
including two ALK-1þ ALCL of the breast
occurring in patients 5–20 years after implantation
of silicone breast prostheses. All of their patients
had lymphoma confined to the breast at the time of
diagnosis; however, 2 suffered recurrences follow-
ing initial therapy [4]. The latter underwent
autologous stem cell transplantation, and showed
no evidence of disease after a 2-year follow-up. A
recent study by de Jong et al. described five
additional cases of ALK-1 negative ALCL
with ‘dominant breast involvement’ occurring in
the fibrous capsules of saline breast implants
placed 1–23 years before diagnosis [3]. Three of
their cases had either bilateral breast involvement
or nodal involvement at time of diagnosis and
seemed to pursue a more aggressive clinical
course, similar to our case. However, it is unclear
if all their cases represented true primary breast
lymphomas.
Although most lymphomas arising in the breast are
of B-cell origin, the majority of those described in
association with breast prostheses have a T-cell
phenotype, and ALCL is the most common type
described. The neoplastic lymphocytes in all pub-
lished studies were negative for ALK-1 expression
[1–3].
Interestingly, in our case, the lymphoma presented
initially in a right axillary LN with a sinusoidal
pattern of infiltration by large undifferentiated
malignant cells, mimicking metastatic breast carci-
noma. This represented a diagnostic challenge,
especially given the remote history of breast carci-
noma. The expression of CD15 was also unusual for
ALCL. In addition, the clinical behaviour of our case
was more aggressive than most cases described
previously.
None of the previously published implant-
associated ALK-1 negative ALCL have described
any cytogenetic or karyotypic aberrations. The
Figure 1. A: Lymph node biopsy showing anaplastic large cells
within sinusoids (H&E, 6200), (B) the cells are CD30 positive
(6400).
Figure 2. A: Anaplastic cells infiltrating the fibrous capsule (H&E,
6400), (B) the cells express CD4 (6400).




















































chromosomal regions altered in our case differ from
those reported in a recent study of systemic ALK-1
negative ALCL [5]. Although cytogenetic aberrations
of chromosome 1, 6 and 13 were noted in our case,
the affected loci differed from those previously
reported.
Despite the reported cases of implant associated
malignancies and the intriguing overrepresentation
of ALK-1 negative ALCL, the incidence of these
types of lymphomas remains extremely low given
that breast prostheses have been widely used for
decades. However, oncologists and pathologists
should be aware of this association and consider
ALCL in their differential diagnosis when examin-
ing tissue removed during capsulectomy for failed
or replacement breast prostheses, or when review
of axillary LNs shows sinusoidal infiltrates of large
cells, even if the patient had a prior history of
carcinoma.
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